Changes in the Expression Landscape of HER2-Negative Breast Cancer under the Influence of Anthracycline-Containing Neoadjuvant Chemotherapy Regimens

Currently, several treatment options are available for patients with HER2 breast cancer; however, there is no gold standard first-line treatment. Anthracycline-containing regimens are also considered traditional systemic treatment as preoperative chemotherapy for this category of patients, and they are a controversial decision due to the high degree of toxicity and low complete pathological response rates. That is why new studies are needed to identify biomarkers that predict response to anthracyclines in NAC HER2-BC, both the presence of pCR and a favorable long-term outcome, to personalize preoperative treatment. In this work, changes were studied in the expression profile of breast tumor of the luminal B HER2-negative subtype under the influence of anthracycline-containing NAC regimens in order to identify the groups of potential expression markers: an objective response to the treatment used and predicting the occurrence of hematogenous metastasis.